## AMENDMENT WITH FINANCIAL DATA SCHEDULE

1

## SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 10-Q/A
Amendment No. 1
/x/ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 1995, or
/ / Transition report pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
for the transition period from to

COMMISSION FILE NUMBER 000-9314

ACCESS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation or organization)

2600 N. Stemmons Frwy, Suite 210
Dallas, TX
(Address of principal executive offices)
83-0221517
(IRS Employer Identification Number)
75207
(Zip Code)
(214) 905-5100
(Registrant's telephone number, including area code)

CHEMEX PHARMACEUTICALS, INC.
600 White Plains Rd., Suite 400
Tarrytown, NY 10591
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or $15(\mathrm{~d})$ of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days.

$$
\text { Yes } / \mathrm{x} / \quad \text { No }
$$

The number of shares outstanding of each of the issuer's classes of common stock was $8,737,788$ shares of common stock, par value, \$.04, outstanding as at November 3, 1995.

## PART II

Item 6. Exhibits and Reports on Form 8-K.
(a) Exhibits
(27) Financial Data Schedule

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date May 16, 1996

> By: /s/ Kerry P. Gray

Kerry P. Gray
(President and
Chief Executive Officer)

```
<TABLE> <S> <C>
<ARTICLE>
5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION FROM THE
CONSOLIDATED BALANCE SHEET AND THE CONSOLIDATED STATEMENT OF
INCOME FILED AS PART OF THE QUARTERLY REPORT ON FROM 10-Q AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH QUARTERLY REPORT ON
FORM 10-Q.
</LEGEND>
<MULTIPLIER>
<S>
<PERIOD-TYPE>
<FISCAL-YEAR-END>
<PERIOD-START>
<PERIOD-END>
<CASH>
<SECURITIES>
<RECEIVABLES>
<ALLOWANCES>
<INVENTORY>
<CURRENT-ASSETS>
<PP&E>
<DEPRECIATION>
<C>
6 4
<TOTAL-ASSETS>
2,417
<CURRENT-LIABILITIES>
                                    1 9 9
<BONDS>
0
<PREFERRED-MANDATORY>
<PREFERRED> 0
<COMMON>
350
<OTHER-SE>
    1,858
<TOTAL-LIABILITY-AND-EQUITY>
<SALES>
2,543
<TOTAL-REVENUES>
<CGS>
<TOTAL-COSTS>
<OTHER-EXPENSES>
<LOSS-PROVISION>
<INTEREST-EXPENSE>
0
<INCOME-PRETAX> 1,997
<INCOME-TAX>
<INCOME-CONTINUING>
0
1,997
<DISCONTINUED>
0
<EXTRAORDINARY>
<CHANGES>
0
<NET-INCOME> 1,997
<EPS-PRIMARY> . }2
<EPS-DILUTED>
.23
```

</TABLE>

